Skip to main content

Table 2 Clinicopathological features and outcomes of 196 HER2-negative luminal breast cancer patients

From: Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer

 

Recurrence

No recurrence

p value

n

9

 

187

  

Mean age (SD)

55.3

(13.9)

55.9

(12.1)

n.s.

Stagea

     

   I

2

 

87

  

  IIA or B

4

 

96

 

<0.01

  IIIA or B

3

 

4

  

Histology

     

  Ductal

7

 

161

  

  Lobular

2

 

11

 

n.s.

  Others

0

 

15

  

High nuclear grade

11%

(1/9)

4%

(7/181)

n.s.

High histological grade

22%

(2/9)

4%

(6/141)

n.s.

ERb

100%

(9/9)

100%

(187/187)

n.s.

PRb

67%

(6/9)

78%

(145/187)

n.s.

Mean Ki67 (%) (SD)

37.9

(21.7)

24.1

(18.5)

<0.05

(Neo-) adjuvant therapy

     

  Endocrine + chemotherapy

9

 

52

  

  Endocrine therapy only

0

 

127

  

  Chemotherapy only

0

 

1

  

  None

0

 

7

  
  1. n.s.: not significant.
  2. adetermined according to pathological findings.
  3. bpercentage of positive (more than 10% of the nuclei of cancer cells) cases.
  4. There were 196 patients with HER2-negative luminal tumours who underwent surgery during the 18-month period starting in April 2010. Compared to the 114 described above, this population includes relatively low-risk patients, i.e. 45% of the 196 patients had Stage I while all of the 114 had stage II or III disease. (Only 31% of this population received NAC plus endocrine therapy).